Facilitation of cholinergic transmission by combined treatment of ondansetron with flumazenil after cortical cholinergic deafferentation.
We have studied the effects of concomitant blockade of 5-HT(3) and GABA(A) receptors on acetylcholine (ACh) release in the frontal cortex of rats with a selective cholinergic lesion. Lesions were performed by microinjection of the cholinergic toxin 192 IgG-saporin into the nucleus basalis magnocellularis. Single treatment with either the 5-HT(3) receptor antagonist ondansetron, 0.1 microg/kg, or the GABA(A) receptor benzodiazepine site antagonist flumazenil, 10 mg/kg, did not affect ACh release. However, the combined ondansetron + flumazenil administration significantly increased ACh release to a similar extent as a depolarising stimulus with K(+), 100 mM, at both 7 and 30 days post-lesion. Cortical perfusion with the combined ondansetron + flumazenil treatment also increased [(3)H]ACh efflux "in vitro" 30 days after lesion, suggesting that local events within the frontal cortex may participate in the interaction of ondansetron with GABAergic neurons, modulating ACh release in situations of cholinergic hypoactivity. No differences in the expression of 5-HT(3) and GABA(A) receptors in the frontal cortex were found after the cholinergic lesion. These results suggest that a combined ondansetron + flumazenil treatment would contribute to restoring a diminished cholinergic function and may provide a basis for using this treatment in the therapy of cognitive disorders associated with degeneration of the cholinergic system.
Gil-Bea
Francisco J
FJ
Department of Pharmacology, School of Medicine, University of Navarra, Irunlarrea 1, 31008 Pamplona, Spain.
Domínguez
Jon
J
García-Alloza
Mónica
M
Marcos
Beatriz
B
Lasheras
Berta
B
Ramírez
María J
MJ
D000109:Acetylcholine / Q000378:metabolism; D000344:Afferent Pathways / Q000502:physiology; D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D003714:Denervation; D005442:Flumazenil / Q000494:pharmacology*; D018755:GABA Agonists / Q000378:metabolism; D018757:GABA Modulators / Q000494:pharmacology*; D058787:GABA-A Receptor Antagonists; D017829:Granisetron / Q000378:metabolism; D008297:Male; D009118:Muscimol / Q000378:metabolism; D017294:Ondansetron / Q000494:pharmacology*; D010275:Parasympathetic Nervous System / Q000187:drug effects*; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011963:Receptors, GABA-A / Q000378:metabolism; D044406:Receptors, Serotonin, 5-HT3 / Q000187:drug effects*; D012702:Serotonin Antagonists / Q000378:metabolism / Q000494:pharmacology*; D009435:Synaptic Transmission / Q000187:drug effects*
D000109:Acetylcholine; D005442:Flumazenil; D018755:GABA Agonists; D018757:GABA Modulators; D058787:GABA-A Receptor Antagonists; D017829:Granisetron; D009118:Muscimol; D017294:Ondansetron; D011188:Potassium; D011963:Receptors, GABA-A; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists